ALG-055009
Metabolic dysfunction-associated steatohepatitis (MASH)
Key Facts
Indication
Metabolic dysfunction-associated steatohepatitis (MASH)
Phase
Phase 2
Status
Active
Company
About Aligos Therapeutics
Aligos Therapeutics is a clinical-stage biotech focused on developing best-in-class therapies for chronic liver and viral diseases, specifically chronic hepatitis B (CHB) and MASH. The company employs a targeted, chemistry-driven approach to design small molecules with optimized pharmacological profiles. Its strategy centers on a lean, experienced team with a proven track record in hepatology and virology drug development, aiming to advance a focused pipeline through key clinical milestones. Despite a challenging financial position with a low market valuation, its progress is defined by upcoming Phase 2 data for its lead assets.
View full company profileTherapeutic Areas
Other Metabolic dysfunction-associated steatohepatitis (MASH) Drugs
| Drug | Company | Phase |
|---|---|---|
| NGM831 (MK-3655) | NGM Biopharmaceuticals | Phase 2b |
| Pegozafermin (BIO89-100) | 89bio | Phase 3 |
| Icosabutate | NorthSea Therapeutics | Phase 3 |
| Oxy210 | MAX BioPharma | Preclinical |
| NA-941 | Biomed | Phase 2A |
| PRO-MSH-001 | ProdIgY Biotech | Discovery |
| Undisclosed MASH Program | Syndya Therapeutics | Discovery |
| Partnered Program | Cellarity | Pre-clinical |
| Lanifibranor | Hepalys | Phase 1 |
| IW-601 | ImmuneWalk Therapeutics | Preclinical |
| ION224 (IONIS-DGAT2Rx) | Ionis Pharmaceuticals | Phase 2b |
| CM-101 | Chemomab Therapeutics | Phase 2a |